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Patients with MT of any age, on ICT for at least three years,
were sequentially enrolled at eight Italian Thalassemia Care
Centers. HRQoL was measured in >14 year-old, patients, who
completed 2 generic instruments, EQ-5D and Short Form-36 (SF-
36). RESULTS: Results refer to 121 patients, with median age =
29.8 (14.1–48.5), 49.6% male. At enrolment 87.6% of patients
had at least one thalassemia related complication, 48.3% were
treated with Deferoxamine, 32.5% treated with Deferiprone,
19.2% were treated with both; 14.0% changed treatment
regimen at least once during the observational period (11.6
median months). EQ-5D proﬁle patients reported moderate
problems with “mobility” (9.1%), “self care” (0.8%), “usual
activities” (23.5%), moderate or severe “pain/discomfort”
(60.5%) and “anxiety/depression” (39.5%). The EQ-Visual
Analogue Scale had a mean = 73.0 (median = 75.0, from 30 to
100). Similar trends were observed with the SF-36 ones: in par-
ticular the mean + SD Physical Component Summary score was
47.7 + 8.4; the mean + SD Mental Component Summary score
was 45.1 + 8.8. CONCLUSIONS: Thalassemic patients have
impaired levels HRQoL: both physical and mental components
seem to be compromised from the disease or ICT and related
consequences. Therapies improving patients’ satisfaction with
and compliance to ICT may have positive consequences not only
on clinical effectiveness but also on overall patient’s wellbeing.
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OBJECTIVES: Patients with thalassemia, sickle cell disease
(SCD), and myelodysplastic syndromes (MDS) require infusion
iron chelation therapy (ICT) involving 8–12 hour infusions, 5
days per week, potentially limiting quality of life (QoL) and
inhibiting adherence in patients already limited by their condi-
tion. Thus, satisfaction with ICT is an important treatment
outcome. To date, there is no well-established measure to quan-
tify patient satisfaction with ICT. The aim of this study is to
describe the development and scoring of a treatment satisfaction
instrument for patients taking ICT. METHODS: Based on a lit-
erature review, and patient and clinician interviews, a 28-item
instrument was developed as funded by Novartis. This included
an assessment of: satisfaction with prior experience with ICT;
satisfaction with ICT characteristics; adherence to treatment;
preferences; and behavioural intentions. U.S. and U.K. patients
with thalassemia, SCD, or MDS (n = 110) currently taking ICT
completed the satisfaction instrument. The scoring of the instru-
ment and the assessment of its reliability and validity was per-
formed on the 19 satisfaction items. The 9 items related to past
experience, intentions and preferences were scored separately.
RESULTS: The Principal Component Analysis using a varimax
rotation revealed a four dimensional structure that explained
63% of the total variance. The factors of the Satisfaction with
ICT instrument were labelled: Perceived Effectiveness of ICT (6
items); Burden of ICT (5 items); Acceptance of ICT (5 items);
and Side-effects of ICT (3 items). Internal consistency reliability
for all subscales was good, with alpha coefﬁcients ranging
between 0.80 for Acceptance of ICT to 0.86 for Perceived Effec-
tiveness. CONCLUSIONS: Preliminary analyses suggest that the
Satisfaction with ICT instrument is reliable. Further validation
of the instrument is required to assess its test-retest reliability,
construct validity and responsiveness. The instrument could be
used in routine clinical practice or in clinical trials to measure
satisfaction with ICT.
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OBJECTIVE: Treatment for hemophilia patients with inhibitors
is costly and challenging for its complexity, without clear agree-
ment on drug selection or optimal dosing regimen for the ﬁrst-
line management of bleeding episodes. This study sought to
identify treatment attributes that are important to hematologists
in the United States. METHODS: A conjoint analysis was con-
ducted to elicit preferences using a discrete choice experiment.
Twelve attributes were assessed: risk of human viral infections,
possibility that the titer of the inhibitor may rise, reduction 
in the likelihood of dose-related thromboembolic events, the
number of infusions required to stop hemorrhage, infusion
preparation time, infusion time, infusion volume, time required
to stop bleeding, time required to alleviate pain, prophylaxis use,
ability to undergo major surgery, and cost of medications. Thirty
hematologists completed questionnaires involving twelve choice
tasks with trade-offs between three scenarios (most likely to use,
no preference, and least likely to use). Data were analyzed using
a multinomial logit model to obtain relative importance of each
attribute. RESULTS: Responding hematologists (with an average
of 13 years of experience treating hemophilia patients with
inhibitors) treat on average a total of 28 patients including four
inhibitor patients per month. “Time required to stop bleeding”
was the most important factor affecting treatment decisions (rel-
ative importance (RI) = 16.3%). Physicians also preferred treat-
ment products that possessed quick pain relief (RI = 12.9%), no
possibility that the titer of inhibitor may rise (RI = 12.8%), fewer
number of infusions required to stop a hemorrhage (RI =
12.7%), and absence of risk of human viral infection (RI =
10.8%). CONCLUSIONS: The study revealed the most impor-
tant attributes of treatment for hemophilia patients with
inhibitors from the physician perspective. Future studies should
compare physician preferences with those of hemophilia patients
with inhibitors.
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Patients with β-Thalassemia Major (MT) require life-long blood
transfusions, which often cause iron overload that, if left
untreated, may increase patients’ morbidity and mortality. Iron
Chelation Treatment (ICT), is based on 8–12 hour infusions of
Deferoxamine for 5–7 days/week and/or Deferiprone orally
administered. ICT aims to reduce iron overload but low satis-
faction and low compliance, lead to potentially negative conse-
quences on treatment effectiveness. OBJECTIVES: To investigate
ICT satisfaction in MT patients and explore its relationship with
their thinking about stopping medication. METHODS: The
